Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT(R) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...
Nasdaq

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...

Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026

Alpha Tau Medical targets major 2026 catalysts as Alpha DaRT gains momentum; key pancreatic & GBM readouts ahead. Read the full analysis here of DRTS stock.
Business Insider

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in patients ...
Hosted on MSN

Alpha Tau expands Alpha DaRT into recurrent prostate cancer: What investors should watch

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is launching a new safety study titled “A Safety Study of ...
Nasdaq

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...
Cleveland.com

Brain tumor breakthrough: First patient receives Alpha DaRT radiation at OSU

CLEVELAND, Ohio — The Ohio State University’s James Cancer Hospital has treated the world’s first brain cancer patient to receive a new radiation technology that attacks tumors from within, the ...
Business Insider

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

- Alpha DaRT pancreatic cancer patient treatments underway in U.S. multi-center pilot study- - Newly received radioactive material license for New Hampshire facility positions the Company for ...
Hosted on MSN

Alpha Tau Medical’s innovative prostate cancer therapy: study completion update

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Alpha Tau Medical Ltd (DRTS) has recently completed a clinical study titled ‘A Feasibility of Neoadjuvant Interstitial ...
Seeking Alpha

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer

JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (DRTS) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, today announced that the ...